BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

805 related articles for article (PubMed ID: 19341365)

  • 1. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.
    Ito K
    Int J Urol; 2009 May; 16(5):458-64. PubMed ID: 19341365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate specific antigen best practice statement: 2009 update.
    Greene KL; Albertsen PC; Babaian RJ; Carter HB; Gann PH; Han M; Kuban DA; Sartor AO; Stanford JL; Zietman A; Carroll P
    J Urol; 2009 Nov; 182(5):2232-41. PubMed ID: 19781717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan.
    Okihara K; Kitamura K; Okada K; Mikami K; Ukimura O; Miki T
    Int J Urol; 2008 Feb; 15(2):156-60; discussion 161. PubMed ID: 18269453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan.
    Ito K; Kakehi Y; Naito S; Okuyama A;
    Int J Urol; 2008 Sep; 15(9):763-8. PubMed ID: 18786203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Advancements in PSA-based screening for prostate cancer].
    Ito K
    Rinsho Byori; 2004 Jul; 52(7):611-7. PubMed ID: 15344561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010.
    ;
    Int J Urol; 2010 Oct; 17(10):830-8. PubMed ID: 20825509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
    Lim LS; Sherin K;
    Am J Prev Med; 2008 Feb; 34(2):164-70. PubMed ID: 18201648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in baseline PSA levels in Japanese men from 1988 to 2003.
    Ohi M; Ito K; Yamamoto T; Miyakubo M; Takechi H; Kubota Y; Suzuki K
    Urology; 2008 Jul; 72(1):95-8. PubMed ID: 18455775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
    Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
    Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
    Agalliu I; Weiss NS; Lin DW; Stanford JL
    Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen doubling time among Japanese men in an annual health screening program.
    Terai A; Matsui Y; Ichioka K; Ohara H; Terada N; Yoshimura K
    Int J Urol; 2004 Oct; 11(10):856-61. PubMed ID: 15479290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prostate cancer and prostate specific antigen screening].
    Camici M
    Minerva Med; 2004 Feb; 95(1):25-34. PubMed ID: 15041924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
    Connolly D; Black A; Gavin A; Keane PF; Murray LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prostate cancer screening].
    Villers A; Rébillard X; Soulié M; Davin JL; Coloby P; Moreau JL; Mejean A; Irani J; Coulange C; Mangin P;
    Prog Urol; 2003 Apr; 13(2):209-14. PubMed ID: 12765053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
    Howard K; Barratt A; Mann GJ; Patel MI
    Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
    Culp S; Porter M
    BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.